Dana-Farber Cancer Institute Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2017
NCT03057145
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Bradley A. McGregor, MD

Active Ingredients

Drugs in Phase 1 Trials (2)

olaparib (lynparza) (1 trial)

prexasertib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2